Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time. Those medications, however, are not without their risks and side effects.

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

Sue Bell became one of the first Alzheimer's patients in the U.S. to receive the drug now marketed as Leqembi. Her husband isn't sure if it made a difference. In 2020, Sue Bell became one of the first ...

Two bills aim to close gaps and ensure equitable access by requiring private health insurance coverage of FDA-approved ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

In what is seen as an unusual decision, the UK’s National Institute for Health and Care Excellence (NICE) says it will ...

Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...

NICE’s interim second draft guidance does not recommend lecanemab for use within the NHS in England and Wales at this time.

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...

The UK’s National Institute for Health and Care Excellence (NICE) has issued further draft guidance reaffirming its decision ...